$20.57
0.10% today
Nasdaq, Nov 04, 06:48 pm CET
ISIN
US80810D1037
Symbol
SDGR

Schrodinger Inc Stock price

$20.55
-0.04 0.19% 1M
-5.43 20.90% 6M
+1.26 6.53% YTD
+2.31 12.66% 1Y
-4.11 16.67% 3Y
-27.51 57.24% 5Y
-8.09 28.25% 10Y
-8.09 28.25% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
-0.49 2.33%

New AI Insights on Schrodinger Inc Insights AI Insights on Schrodinger Inc

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.1b
Net debt
positive
Cash
$450.2m
Shares outstanding
73.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.4 | 5.9
EV/Sales
4.5 | 4.2
EV/FCF
43.6
P/B
4.4
Financial Health
Equity Ratio
51.2%
Return on Equity
-44.4%
ROCE
-36.2%
ROIC
-144.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$237.9m | $254.7m
EBITDA
$-186.5m | $-169.5m
EBIT
$-192.9m | $-189.4m
Net Income
$-181.3m | $-175.3m
Free Cash Flow
$24.4m
Growth (TTM | estimate)
Revenue
18.6% | 22.7%
EBITDA
7.0% | 16.6%
EBIT
6.3% | 9.5%
Net Income
10.0% | 6.3%
Free Cash Flow
112.7%
Margin (TTM | estimate)
Gross
58.5%
EBITDA
-78.4% | -66.5%
EBIT
-81.1%
Net
-76.2% | -68.8%
Free Cash Flow
10.2%
More
EPS
$-2.5
FCF per Share
$0.3
Short interest
23.9%
Employees
891
Rev per Employee
$230.0k
Show more

Is Schrodinger Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Schrodinger Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Schrodinger Inc forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Schrodinger Inc forecast:

Buy
75%
Hold
25%

Financial data from Schrodinger Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
238 238
19% 19%
100%
- Direct Costs 99 99
43% 43%
42%
139 139
6% 6%
58%
- Selling and Administrative Expenses 143 143
4% 4%
60%
- Research and Development Expense 189 189
5% 5%
80%
-186 -186
7% 7%
-78%
- Depreciation and Amortization 6.44 6.44
18% 18%
3%
EBIT (Operating Income) EBIT -193 -193
6% 6%
-81%
Net Profit -181 -181
10% 10%
-76%

In millions USD.

Don't miss a Thing! We will send you all news about Schrodinger Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Schrodinger Inc Stock News

Neutral
Business Wire
5 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (Nasdaq: SDGR), the companies have surpassed the final technical milestone for their jointly-developed ammonia synthesis catalyst, branded NeptuneTM. The Neptune catalyst demonstrated an ammonia yield that was over two times higher than that of competing catalysts...
Neutral
Business Wire
13 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. A...
Neutral
Business Wire
20 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on October 13, 2025, the company granted restricted stock units (RSUs) with respect to 14,888 shares of the company's common stock to 10 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors...
More Schrodinger Inc News

Company Profile

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.

Head office United States
CEO Ramy Farid
Employees 891
Founded 1990
Website www.schrodinger.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today